Richard Atkins’ Post

InduPro is delighted to announce the publication of a new review article featured on the cover of Cell Chemical Biology titled, “Therapeutic potential of cis-targeting bispecific antibodies”, which serves to highlight our position at the forefront of developing next generation proximity based cis-bispecific targeting modalities. In this review, InduPro Scientific Founders and Leadersip- Rob Oslund, Pamela Holland, Scott Lesley and Niyi Fadeyi- discuss the progress and impact of cis-bispecific antibodies (cis-bsAbs) in the clinic, their wide-ranging clinical applications, and untangle the intricacies of improving bsAb discovery and development. They further highlight emerging therapeutic strategies to develop next generation cis-bsAbs that include our novel proximity based co-targeting approach leveraging InduPro's Tumor Associated Proximity Antigens (TAPAs) for selective tumor targeting.   https://lnkd.in/ee-ZWb9A #cis-bispecific-targeting #protein-proximity  #proximitybydesign #ProXiMATE #induprotx

evitria’s journal club - paper of the week no. 48 A Conditionally Activated Cytosol-Penetrating Antibody for TME-Dependent Intracellular Cargo Delivery Carolin Dombrowsky et al. (March 2024) Excited to share groundbreaking research from Harald Kolmar's group at the Technical University of Darmstadt! They developed a conditionally activated cytosol-penetrating antibody for tumor microenvironment (TME)-dependent intracellular cargo delivery. This innovative approach uses a heparin sulfate proteoglycan (HSPG)-binding antibody that localizes to the cytosol, delivering cargo proteins up to 70 kDa🦾By leveraging MMP-9 protease cleavage in the TME, they achieve targeted activation and efficient intracellular delivery. A promising platform for future cancer therapies! Looking to advance your antibody therapeutics? Get in touch with our scientists to learn how we can support you: www.evitria.com/contact #Biotech #AntibodyEngineering #AntibodyTherapeutics

Struggling with transducing NK cells or gdT cells? Register for this webinar to learn about Miltenyi’s new solutions… #cellandgenetherapy #allogeneic #NKcells #gammadeltaTcells

#Primary_Cells Market Along with an In-depth Analysis of the Competitive Landscape 2023-2032 >> https://lnkd.in/du4icTFK #Primary cells are defined as #cells that are #extracted directly from living #tissues of either #humans or #animals and then undergo #processing to make them #suitable for use in appropriate cell #therapies. Primary cells are #extensively used in #numerous areas, like #3D cell #culture, virology, cancer research, #stem cell therapy, and tissue #replacement. Thermo Fisher Scientific, Merck KGaA, Darmstadt, Germany, Lonza, Cell Biologics, Inc, PromoCell, ZenBio, STEMCELL Technologies, AllCells, ATCC-American-Type-Culture-Collection, Axol Bioscience Ltd. #primarycells #tissues #humans #animals #biotechnology #medicalscience

#citations Remarkable discovery! Vividion Therapeutics, Inc. discovered a promising drug candidate! GenScript is honored to provide service for this amazing work! WRN, a DNA repair helicase, is a highly valuable drug target. Loss of WRN was identified as a strong vulnerability of microsatellite instable (MSI) cancers. Currently there are no approved drugs directly targeting human DNA or RNA helicases due to the difficulty of inhibit. Researchers from Vividion Therapeutics developed VVD-133214, a clinical-stage, covalent allosteric inhibitor of WRN helicase through chemical proteomics. VVD-133214 was well tolerated in mice and led to robust tumor regression in multiple microsatellite-instability-high colorectal cancer cell lines and patient-derived xenograft models. 👉Read more: https://lnkd.in/ekBGKQJg Congratulations to Vividion Therapeutics and all contributors! Kristen Baltgalvis Jonathan Pollock  Chu-Chiao (Crystal) Wu, MS, PhD Thomas Glaza  GenScript have extensive experience in various drug target protein. Our guaranteed package ensures the delivery of a guaranteed amount and high-purity drug target protein, facilitating the progress of your drug discovery projects. 👉Learn more about GenScript Insect protein expression service : https://lnkd.in/eAtiu3qb #drugdiscovery #WRN #researchadvance #breakthrough #drugtarget #biotech #proteinexpression

Miltenyi Bioindustry recently launched our preclinical service for BaEV-pseudotyped lentiviral vector. "Standard" VSVg lentiviral vectors bind to cells by the LDL receptor, which is not generally found in sufficient density on certain cell types, such as NK cells, gamma delta T cells, and a few others; yielding low transduction efficiency. Join Han-Hsuan Fu's webinar on July 10 to learn how BaEV-pseudotyped lentiviral vector can efficiency transduce NK cells and see how we've approaching at-scale production of allogeneic cell products on the CliniMACS Prodigy. https://lnkd.in/eATT967B

🔬 A new review by researchers from Université Claude Bernard Lyon 1 describes next-generation prospects for antibody–drug conjugates (ADCs). In the coming months, three ADCs should receive marketing authorization to treat various forms of NSCLC in adults: datopotamab deruxtecan, patritumab deruxtecan, and telisotuzumab vedotin. • Thirteen antibody–drug conjugates (ADCs) are currently commercially available. • The drug:antibody ratio must reflect the precision of the conjugation process used. • In addition to mastering linker design and payload selection, target diversification remains crucial. Read the full review here 👉 https://lnkd.in/eNVvqmPi #Biointron #Antibodies #ADC #DrugDevelopment #Oncology Study by Meriem Grairi & Marc Le Borgne

In our ongoing series on bispecific antibody formats, we’ve explored several innovative options, including Crossmab, the Duobody system, IgG-scFvs, and advanced techniques like Knobs-into-Holes and Electrostatic Steering. These formats offer unique benefits and are pivotal in advancing therapeutic development. At evitria, we are dedicated to supporting your research and development needs in bispecific antibody technology. Whether you’re navigating established formats or exploring cutting-edge technologies, evitria is here to support your journey. Reach out to us for expert guidance on bispecific antibodies and discover how we can help advance your research. 🧪 #BispecificAntibodies #DrugDiscovery #Oncology #Cancerresearch #Biotechnology #Antibodies

Jerome Boyd-Kirkup, Chief Scientific Officer at Hummingbird Bioscience, will be presenting our novel dual-payload technologies at Antibody Engineering & Therapeutics San Diego. Read more in the interview: https://bit.ly/4ioDXPY Our potentially first-in-class dual-payload ADC platform strategically combines two payloads in a manner that meaningfully potentiates cytotoxic activity in targeted cancer cells. Jerome will present the possibilities of this platform and share efficacy and safety data on HMBD-802, a HER2-targeted dual-payload ADC that could unlock new opportunities in areas of high unmet medical need.   If you will be at Antibody Engineering & Therapeutics San Diego, attend the talk to learn more. #adc #drugresistance #biotech 

The use of microfluidic technology in single-cell assay has shown potential in biomedical applications like protein quantification, immune response monitoring, and drug discovery. Because of the details of information that can be obtained at single-cell resolution, the single-cell assay has been applied to tackle challenging issues such as cancer treatment. Information like the levels of protein expression, cellular heterogeneity, and unique behaviors within subsets are very important in the biomedical field. For a single-cell assay system, a high-throughput platform that can do on-demand media exchange and real-time monitoring is advantageous in single-cell screening and profiling. In this work, a high-throughput valve-based device is presented, its use in single-cell assay, particularly in protein quantification and surface-marker analysis, and its potential application to immune response monitoring and drug discovery are laid down in detail. https://lnkd.in/e2mz6r5j